FDA approves Mitsubishi's ALS drug

FDA approved Radicava edaravone from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) to treat amyotrophic lateral sclerosis. Mitsubishi said it is the first drug FDA has approved for ALS in more than 20 years.

Mitsubishi Tanabe Pharma America Chief Commercial Officer Tom Larson told BioCentury that Radicava will be available in early to mid-August at an annual price of about $145,000...